Transforming growth factor-β promotes prostate bone metastasis through induction of microRNA-96 and activation of the mTOR pathway

Oncogene

Volumn 34, Issue 36, 2015, Pages 4767-4776

  Siu, M K ^a,b   Tsai, Y C ^a   Chang, Y S ^a   Yin, J J ^c   Suau, F ^c   Chen, W Y ^b   Liu, Y N ^a  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AKT1S1 PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MICRORNA; MICRORNA 96; PROTEIN KINASE B; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; AKT1S1 PROTEIN, HUMAN; MIRN96 MICRORNA, HUMAN; MTOR PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; CELL GROWTH; CELL INVASION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; UPREGULATION; 3' UNTRANSLATED REGION; ANIMAL; BIOSYNTHESIS; BONE TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MOUSE; PATHOLOGY; PROSTATE TUMOR; SECONDARY; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICRORNAS; PROSTATIC NEOPLASMS; SMAD PROTEINS; TOR SERINE-THREONINE KINASES; TRANSFORMING GROWTH FACTOR BETA;

EID: 84940961003     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.414     Document Type: Article

References (37)

1. Ikushima H, Miyazono K. TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer 2010; 10: 415-424.
2. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004; 303: 848-851.
3. Li X, Placencio V, Iturregui JM, Uwamariya C, Sharif-Afshar AR, Koyama T et al. Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis. Oncogene 2008; 27: 7118-7130.
4. Ao M, Williams K, Bhowmick NA, Hayward SW. Transforming growth factor-beta promotes invasion in tumorigenic but not in nontumorigenic human prostatic epithelial cells. Cancer Res 2006; 66: 8007-8016.
5. Lee C, Sintich SM, Mathews EP, Shah AH, Kundu SD, Perry KT et al. Transforming growth factor-beta in benign and malignant prostate. Prostate 1999; 39: 285-290.
6. Tian M, Schiemann WP. The TGF-beta paradox in human cancer: an update. Future Oncol 2009; 5: 259-271.
7. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGFbeta family signalling. Nature 2003; 425: 577-584.
8. Lamouille S, Derynck R. Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J Cell Biol 2007; 178: 437-451.
9. Lamouille S, Connolly E, Smyth JW, Akhurst RJ, Derynck R. TGF-beta-induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion. J Cell Sci 2012; 125: 1259-1273.
10. Bertoldo F, Silvestris F, Ibrahim T, Cognetti F, Generali D, Ripamonti CI et al. Targeting bone metastatic cancer: role of the mTOR pathway. Biochim Biophys Acta 2014; 1845: 248-254.
11. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007. 12. 9-22.
12. Sancak Y, Thoreen CC, Peterson TR, Lindquist RA, Kang SA, Spooner E et al. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol cell 2007; 25: 903-915.
13. Vander Haar E, Lee SI, Bandhakavi S, Griffin TJ, Kim DH. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol 2007; 9: 316-323.
14. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011; 12: 21-35.
15. Nicoloso MS, Spizzo R, Shimizu M, Rossi S, Calin GA. MicroRNAs-the micro steering wheel of tumour metastases. Nat Rev Cancer 2009; 9: 293-302.
16. Butz H, Racz K, Hunyady L, Patocs A. Crosstalk between TGF-beta signaling and the microRNA machinery. Trends Pharmacol Sci 2012; 33: 382-393.
17. Liu YN, Abou-Kheir W, Yin JJ, Fang L, Hynes P, Casey O et al. Critical and reciprocal regulation of KLF4 and SLUG in transforming growth factor beta-initiated prostate cancer epithelial-mesenchymal transition. Mol Cell Biol 2012; 32: 941-953.
18. Liu YN, Yin JJ, Abou-Kheir W, Hynes PG, Casey OM, Fang L et al. MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms. Oncogene 2013; 32: 296-306.
19. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18: 11-22.
20. Haflidadottir BS, Larne O, Martin M, Persson M, Edsjo A, Bjartell A et al. Upregulation of miR-96 enhances cellular proliferation of prostate cancer cells through FOXO1. PLoS ONE 2013; 8: e72400.
21. Yin JJ, Zhang L, Munasinghe J, Linnoila RI, Kelly K. Cediranib/AZD2171 inhibits bone and brain metastasis in a preclinical model of advanced prostate cancer. Cancer Res 2010; 70: 8662-8673.
22. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004; 10: 594-601.
23. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005; 436: 725-730.
24. Martin P, Liu YN, Pierce R, Abou-Kheir W, Casey O, Seng V et al. Prostate epithelial Pten/TP53 loss leads to transformation of multipotential progenitors and epithelial to mesenchymal transition. Am J Pathol 2011; 179: 422-435.
25. Fendler A, Jung M, Stephan C, Erbersdobler A, Jung K, Yousef GM. The antiapoptotic function of miR-96 in prostate cancer by inhibition of FOXO1. PLoS ONE 2013; 8: e80807.
26. Lin H, Dai T, Xiong H, Zhao X, Chen X, Yu C et al. Unregulated miR-96 induces cell proliferation in human breast cancer by downregulating transcriptional factor FOXO3a. PLoS ONE 2010; 5: e15797.
27. Yu S, Lu Z, Liu C, Meng Y, Ma Y, Zhao W et al. miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. Cancer Res 2010; 70: 6015-6025.
28. Bedi A, Chang X, Noonan K, Pham V, Bedi R, Fertig EJ et al. Inhibition of TGF-beta enhances the in vivo antitumor efficacy of EGF receptor-targeted therapy. Mol Cancer Ther 2012; 11: 2429-2439.
29. Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 2014; 508: 118-122.
30. Brown K, Quintanilla M, Ramsden M, Kerr IB, Young S, Balmain A. v-ras genes from Harvey and BALB murine sarcoma viruses can act as initiators of two-stage mouse skin carcinogenesis. Cell 1986; 46: 447-456.
31. Yadav V, Sultana S, Yadav J, Saini N. Gatifloxacin induces S and G2-phase cell cycle arrest in pancreatic cancer cells via p21/p27/p53. PLoS ONE 2012; 7: e47796.
32. Gogna R, Madan E, Kuppusamy P, Pati U. Re-oxygenation causes hypoxic tumor regression through restoration of p53 wild-type conformation and posttranslational modifications. Cell Death Dis 2012; 3: e286.
33. Liu C, Zhu Y, Lou W, Nadiminty N, Chen X, Zhou Q et al. Functional p53 determines docetaxel sensitivity in prostate cancer cells. Prostate 2013; 73: 418-427.
34. Skjoth IH, Issinger OG. Profiling of signaling molecules in four different human prostate carcinoma cell lines before and after induction of apoptosis. Int J Oncol 2006; 28: 217-229.
35. Mishra S, Deng JJ, Gowda PS, Rao MK, Lin CL, Chen CL et al. Androgen receptor and microRNA-21 axis downregulates transforming growth factor beta receptor II (TGFBR2) expression in prostate cancer. Oncogene 2014; 33: 4097-4106.
36. Yin J, Pollock C, Tracy K, Chock M, Martin P, Oberst M et al. Activation of the RalGEF/Ral pathway promotes prostate cancer metastasis to bone. Mol Cell Biol 2007; 27: 7538-7550.
37. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550.